32 results
Thumbnail

D2.245 - Dithranol loaded Dendritic nanoarchitectures for the treatment of psoriasis

Thumbnail

D2.246 - Occupational contact dermatitis to chromium in guitarist

Thumbnail

D2.247 - Vitamin D Status as a Modifiable Factor in Chronic Spontaneous Urticaria

Thumbnail

D2.249 - The impact of the coronavirus infection and vaccination against SARS-CoV-2 in the course of chronic urticaria

Thumbnail

D2.251 - Allergic Contact Dermatitis to Clonidine Transdermal Patch: Insights From a Rare Case With Prolonged Cutaneous Exposure

Thumbnail

D2.254 - Thyroid Autoantibody Seroconversion in Chronic Spontaneous Urticaria: Insights from Omalizumab Treated Patients

Thumbnail

D2.255 - Adult-onset Still’s disease mimicking chronic spontaneous urticaria: a case report

Thumbnail

D2.259 - Beyond Contact with Water: A Case of Aquagenic Urticaria

Thumbnail

D2.250 - Sensitivity to Dental Materials and Its Clinical Implications: A Retrospective Patch Test Study

Thumbnail

D2.248 - Asthma control in patients with moderate-to-severe atopic dermatitis and comorbid-asthma treated with lebrikizumab in a real-world-setting: interim analysis of the non-interventional study ADLife

Thumbnail

D2.252 - Occupational Allergic Contact Dermatitis: Impact on Work Productivity and Professional Activity

Thumbnail

D2.253 - Trends in Allergic Contact Dermatitis to Metals According to Gender

Thumbnail

D2.256 - Aquagenic syringeal acrokeratoderma: a diagnostic challenge triggered by water exposure

Thumbnail

D2.257 - Is It Beneficial To Expand The Allergy Test Panel Based On Component-Based Test Results In Chronic Urticaria?

Thumbnail

D2.260 - The Burden of Chronic Urticaria

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study